India's BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drug
MUMBAI, March 18
MUMBAI, March 18 (Reuters) - India's BDR Pharmaceuticals International Pvt Ltd has applied to the Indian patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, dasatinib, through a so-called compulsory licence mechanism, a BDR executive said on Monday.
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licences for certain drugs that are deemed unaffordable to a large section of their populations.
Early this month, Bayer AG lost an appeal challenging the first-ever compulsory licence issued by India which allowed Natco Pharma to sell a version of the German drugmaker's cancer treatment Nexavar.
- Radar showed missing plane may have turned back: Malaysia military
- Malaysian jetliner may have turned back before vanishing |
- Malaysian plane presumed crashed; questions over false IDs |
- Exclusive: Probe into missing Malaysia plane looks at possible mid-air disintegration - source